57 results about "Dna immunization" patented technology

Vectors for DNA immunization against cervical cancer comprise a nucleic acid molecule encoding at least one non-toxic T-cell epitope of the E6 and/or E7 antigens of a strain of human papilloma virus (HPV) associated with cervical cancer, such as HPV-16, and a promoter operatively coupled to the nucleic acid molecule for expression of the nucleic acid molecule in a host to which the vector is administered.

Nucleic acid, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of Chlamydia, preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

Disclosed are peptide and DNA compositions surprisingly found to be effective in generating immune responses against the pathogenic fungi Coccidioides spp., the causative agents of coccidioidomycosis and Valley Fever. The invention thus provides peptides and DNA constructs, combinations and related biological compositions, and prophylactic and therapeutic methods of using such components to generate effective immune responses against Coccidioides spp., including C. immitis.

The invention relates to DNA immunity adsorbent and a preparation method thereof. The DNA immunity adsorbent comprises an adsorbent carrier loaded with DNA. The DNA immunity adsorbent further comprises a cross-linking polyvinyl alcohol film mixed with DNA to achieve a film wrapping effect for the adsorbent. The preparation method includes the following step of sequentially conducting cross-linking and film wrapping or sequentially conducting film wrapping and cross-linking. The DNA immunity adsorbent has adsorption performance for anti-double stranded DNA antibodies in SLE patient plasma, and is superior to DNA immunity adsorbent prepared from a collodion wrapping film in general.

The present invention relates to antibodies and antigen binding fragments thereof derived from antibodies raised by DNA immunization of host animals, particularly camelids (e.g. llama). The antibodies and antigen binding fragments thereof bind to proteins which may be particularly large in size (at least 1115 amino acids in length), or have at least 8 transmembrane domains, or are naturally encoded by nucleotide sequences which are difficult to replicate in standard or common E. coli strains. The present invention also relates to antibodies and antigen binding fragments thereof which bind to ion channels, in particular the voltage-gated sodium channel Nav1.7. Methods of raising antibodies against particular protein targets by a process of DNA immunization are also provided.

The invention relates to methods for separating and identifying DNA (deoxyribonucleic acid) binding protein, in particular to methods for separating and identifying DNA binding protein through a DNA co-immunoprecipitation technology. The separating method comprises the steps of extracting nucleoprotein of a cell, mixing a target DNA molecule and nucleoprotein, adding a molecular entity capable of being bound with the target DNA molecule, separating to obtain a nucleoprotein ingredient bound with the target DNA molecule, further separating the obtained nucleoprotein ingredient, and obtaining the DNA binding protein. The identifying method further comprises the step of identifying the DNA binding protein obtained by separating. The methods have the characteristics of good stability and repeatability, and significantly improve the experiment efficiency of identifying the unknown DNA binding protein. The methods provide beneficial help for subjects such as molecular behavioristics, molecular oncology, cytobiology and biochemistry deeply researching into cytogene transcriptional control and genetic transcription.

We describe a bacterial delivery system for the delivery of DNA and antigens into cells. We constructed an attenuated bacterial vector which enters mammalian cells and ruptures delivering functional plasmid DNA and antigens into the cell cytoplasm. This Shigella vector was designed to deliver DNA to colonic surfaces, thus opening the possibility of oral and other mucosal DNA immunization and gene therapy strategies. The attenuated Shigella is also useful as a vaccine for reducing disease symptoms caused by Shigella.

The invention discloses monoclonal antibodies of avian influenza H5HA antigens, belonging to the field of biotechnology. The invention provides H5-VN HA genes optimized by the codon of which the sequence is SEQ ID NO.1, and the sequence is used for preparing a monoclonal antibody 3B2IIG8F6 and a monoclonal antibody 4B10IIH4G12 of avian influenza H5-VN HA antigens through DNA immunization and a hybridoma cell CGMCC No.3648 and a hybridoma cell CGMCC No.3649 for secreting the two monoclonal antibodies. The H5-VN HA genes optimized by the codon, which is provided by the invention, can improve the expression of HA genes. In addition, the sequence optimization also enables mRNA to be more stable, and genes can be transcribed and translated more easily. The monoclonal antibodies of H5HA antigens, which are prepared by the invention, provide beneficial tools for research and clinical application of avian influenza viruses.

The invention provides a system of providing and creating personalized immunotherapeutic compositions for a subject having a disease or condition, including therapeutic immunotherapy delivery vectorsand methods of making the same comprising gene expression constructs expressing peptides associated with one or more neo-epitopes or peptides containing mutations that are specific to a subject's cancer or unhealthy tissue. A delivery vector of the invention includes bacterial vectors including Listeria bacterial vectors; or viral vectors, peptide immunotherapy vectors; or DNA immunotherapy vectors, comprising one or more fusion proteins comprising one or more peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. This invention also provides methods of using the delivery vector for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection, or an autoimmune disease or an organ transplant rejection in the subject.

Nucleic acid, including DNA, for immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of Chlamydia, preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

A method for preparing a carbonized resin DNA immunoadsorbent, which uses styrene, acrylonitrile, divinylbenzene, toluene, liquid paraffin, benzoyl peroxide and water solution of polyvinyl alcohol as raw materials, produces a DNA immunoadsorbent with 0.3-0.5 mg DNA per milliliter of resin using two-staged procedures for preparation of first carbonized resin, and secondly carbonized resin DNA immunoadsorbent. The resultant immunoadsorbent is high in adsorbent capacity, low in production cost, and can be synthesized without pyrogens. It therefore satisfies the demands of medical application for the treatment of systemic lupus erythematosus by immunoadsorption.

A high-throughput process of generating expression-competent, antigen-encoding immunogen DNA through amplification methodology including ligation-assisted PCR is described, as well as the use of the DNA for methods of DNA immunization. Also described is an adjuvant plasmid to enhance antibody production.

The invention relates to a preparation process for a hybridoma secreting a monoclonal antibody repelling human asparaginate hydroxylase. The method comprises the following steps: taking the recombinant enkaryon expression plasmid DNA of a human asparaginate hydroxylase HAAH coded gene, injecting the DNA into the skeletal muscle of a white rat for DNA immunity, carrying out human asparaginate hydroxylase HAAH recombinant protein immunity after 1 to 4 weeks, taking the splenic cell and myeloma cell of the immune white rat for cell fusion after 2 to 5 days, carrying out antibody detection, and cloning the positive cells in the antibody detection till obtaining the hybridoma secreting the monoclonal antibody repelling human asparaginate hydroxylase. The invention solves the technical problems of bad specificity, long immune cycle and low efficiency in the prior art. The hybridoma has clear immunogenicity, high purity, few non-specific reactions, and low use level of antigen with a total immune cycle of only 6 to 8 weeks.